Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) this morning announced that it has retained Cannabis Compliance Inc. (“CCI”) in order to submit an application, on behalf of Agro-Biotech Inc., to Health Canada for a dealer’s license under the Controlled Drugs and Substances Act and the Narcotic Control Regulations enacted thereunder. This morning’s update comes on the heels of a February 22 announcement of Pivot’s entry into a letter of intent for the proposed acquisition of Agro-Biotech. “The addition of a Dealer’s License for the Agro-Biotech facility will allow the Company to exercise complete control of our finished products, from seed to derivatives,” Dr. Patrick Frankham, CEO of Pivot, stated in the news release. “With access to 10,000 kg of cannabis annually, the ability to extract, purify and formulate in-house, Pivot will provide the most exceptional quality, dosable products available on the market. This vertical integration makes Pivot a differentiated player in the cannabis industry.”
To view the full press release, visit http://ibn.fm/BT96w
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot Pharmaceutical’s subsidiary, Pivot Green Stream Health Solutions Inc., will focus on improving the bioavailability of cannabinoid-based pharmaceuticals. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids that can receive a Health Canada Natural Health Product designation. For more information, visit www.PivotPharma.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
